[Comment] Nirsevimab over two RSV seasons: do the findings align with expectations?
Summary
The implementation of early respiratory syncytial virus (RSV) infection prevention with the long-acting monoclonal antibody nirsevimab during the 2023–24 cold season marked a major turning point for infants and for health-care systems as a whole.1 In countries where nirsevimab was introduced in the northern hemisphere, the first season of its use was associated with a striking reduction in RSV bronchiolitis, in both…
The implementation of early respiratory syncytial virus (RSV) infection prevention with the long-acting monoclonal antibody nirsevimab during the 2023–24 cold season marked a major turning point for infants and for health-care systems as a whole.1 In countries where nirsevimab was introduced in the northern hemisphere, the first season of its use was associated with a striking reduction in RSV bronchiolitis, in both hospital and ambulatory settings.1,2 Notably, although RSV-A was predominant during the 2023–24 season, whereas RSV-B was predominant during the 2024–25 season, the effectiveness of nirsevimab was nevertheless confirmed for both seasons, both for bronchiolitis cases requiring hospitalisation and for those managed in the community.